Early-stage translational research to enable discovery of novel, non-opioid, non-addictive pain therapeutics. Supports assay development/validation, screening to find initial hits, in vitro characterization, and limited preliminary in vivo PK/PD/efficacy to prepare projects for later-stage programs.
Eligibility Criteria:
-
Organizations: higher education, nonprofits, for-profits (incl. small businesses), local/state/tribal/federal entities; foreign organizations are not eligible; foreign components of U.S. organizations are allowed.
-
PD/PI must have an eRA Commons ID.
-
Multiple applications allowed if scientifically distinct.
-
Clinical trials are not allowed.
Funding Details:
-
Mechanism: R61/R33 phased award.
-
Budget: up to USD 350,000 in direct costs per year.
Deadline:
-
Letter of intent: 30 days before due date.
-
Application due (5:00 PM local time): September 17, 2025; January 16, 2026; May 15, 2026; September 17, 2026; January 15, 2027.
Where to Go for Further Information:
-
Scientific contact: Julia L. Bachman — [email protected].
-
General grants info: [email protected].